BTEC.L
iShares Nasdaq US Biotechnology UCITS ETF
US
EQUITY
Passive
MANAGEMENT STYLE
$ 930.4 M
ASSETS UNDER MGMT
35 bp
EXPENSES
Fund Basics
| Inception date | Oct 19, 2017 |
| Regulation | UCITS |
| ISIN | IE00BYXG2H39 |
| Distributions | |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| VERTEX PHARMACEUTICALS INC | 8.7 % |
| GILEAD SCIENCES INC | 8.4 % |
| AMGEN INC | 8.1 % |
| REGENERON PHARMACEUTICALS | 5.8 % |
| ALNYLAM PHARMACEUTICALS INC | 3.6 % |
| INSMED INC | 2.5 % |
| BIOGEN IDEC INC | 1.9 % |
| ARGENX SE ADR | 1.8 % |
| ILLUMINA INC | 1.8 % |
| REVOLUTION MEDICINES, INC. | 1.7 % |
Constituent Breakdown
| Number of holdings | 272 |
| Herfindahl-Hirschman Index | 314 |
| Wgt avg mkt cap (mns) | $52,100 |
| Large cap (>$10bn) | 66.2% |
| Mid cap ($2-10bn) | 16.3% |
| Small cap (<$2bn) | 11.2% |
| Developed mkts. | 94.9% |
| Emerging mkts. | 0.9% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 86.5 % |
 |
NETHERLANDS | 1.9 % |
 |
BRITAIN | 1.5 % |
 |
IRELAND | 1.2 % |
 |
DENMARK | 1.2 % |
 |
GERMANY | 1.0 % |
 |
FRANCE | 0.9 % |
 |
CHINA | 0.9 % |
Historical Performance
Standardized Performance (as of 02/28/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 5.7% | 35.6% | 16.7% | 14.4% | 4.6% | -- | -- | 7.2% |
| Dividend Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -- | -- | 0.0% |
| Total Returns | 5.7% | 35.6% | 16.7% | 14.4% | 4.6% | -- | -- | 7.2% | Ann. Volatility | 20.8% | 21.6% | 20.1% | 18.7% | 21.5% | -- | -- | 22.5% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.07 | 0% |
| MSCI EAFE | 0.22 | 3% |
| MSCI Emg Mkts | 0.24 | 4% |
Liquidity Measures
| Avg. volume (000) | 92 |
| ADV traded (mns) | $1 |
| Turnover | 0.1% |
| Avg. Bid/Ask (% of price) | 0.00% |
Technical Indicators
| 30d moving avg. (EMA) | $8.63 |
| Relative strength (RSI) | 57 |
| MACD/Signal | 0.06/0.06 |
| Bollinger Bands (Upper/Lower) | $8.85/$8.49 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. BTEC.L |
Expenses vs. BTEC.L |
ALTAR Score™ vs. BTEC.L |
|---|---|---|---|---|
| BTEE.L | iShares Nasdaq US Biotechnology UCITS ETF | 96.3% | 0 bp | 0.0% |
| XGEN.DE | Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 31.0% | -5 bp | +0.6% |
| XDG3.DE | Xtrackers MSCI Global SDG 3 Good Health UCITS ETF 1C | 22.0% | 0 bp | +6.3% |
| HEAL.L | iShares Healthcare Innovation UCITS ETF | 21.6% | +5 bp | +2.7% |
| GNOM.L | Global X Genomics & Biotechnology UCITs ETF | 19.7% | +15 bp | -3.2% |
| XUHC.DE | Xtrackers MSCI USA Health Care UCITS ETF 1D | 12.2% | -23 bp | +7.0% |
| XUHL.DE | Xtrackers MSCI USA Health Care UCITS ETF 1C | 12.2% | -23 bp | +6.7% |
| XNNV.DE | Xtrackers MSCI Innovation UCITS ETF 1C | 12.2% | -5 bp | +4.1% |
| XDGI.L | Xtrackers MSCI Global SDGs UCITS ETF 1C | 11.9% | 0 bp | +5.1% |
| IUHC.L | iShares S&P 500 Health Care Sector UCITS ETF | 10.7% | -20 bp | +7.3% |
Risk and Returns: BTEC.L vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 4/5/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-0.2%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 1,196 funds in the US Equity category with an average
ALTAR Score™ of 5.7% and a standard deviation
of 2.1%. BTEC.L's ALTAR Score™ is approximately -2.9 standard
deviations above the category average. This places BTEC.L in the 1st percentile
among funds in the category.
Sell-Side Consensus
$10.54
PRICE TARGET
+24.0%
UPSIDE